Biphasic insulin aspart 30 (BIAsp 30) in clinical reality: Experience from a Dutch practice

被引：0

|

作者：

Ligthelm, Robert J.

机构：

来源：

DIABETES | 2007年 / 56卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A540 / A540

页数：1

相关论文

共 50 条

[31] Clinical Effectiveness of Biphasic Insulin Aspart 30:70 Versus Biphasic Human Insulin 30 in UK General Clinical Practice: A Retrospective Database Study (vol 1, pg 27, 2011)
Morgan, C. Ll
CLINICAL THERAPEUTICS, 2011, 33 (03) : 391 - 391
[32] Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study
Khutsoane, D.
Sharma, S. K.
Almustafa, M.
Jang, H. C.
Azar, S. T.
Danciulescu, R.
Shestakova, M.
Ayad, N. M. A.
Guler, S.
Bech, O. M.
DIABETES OBESITY & METABOLISM, 2008, 10 (03): : 212 - 222
[33] Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
Gumprecht, J.
Benroubi, M.
Borzi, V.
Kawamori, R.
Shaban, J.
Shah, S.
Shestakova, M.
Wenying, Y.
Ligthelm, R.
Valensi, P.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (06) : 966 - 972
[34] Biphasic Insulin Aspart 30 (BIAsp 30) Improves Glycemic Control in Patients with Type 2 Diabetes Regardless of Previous Treatment Regimens: The IMPROVE Study in Iran
Esteghamati, Alireza
Rajabian, Reza
Amini, Masoud
Bahrami, Amir
Khamseh, Mohammad Ebrahim
Ardekani, Mohammad
Rizi, Ehsan Parvaresh
DIABETES, 2009, 58 : A516 - A516
[35] Switch from premix human insulin (Mixtard30) in NovoLetto biphasic insulin aspart (NovoMix 30) in FlexPen: 'Experiences learned from practice in the Netherlands'
Appelman-Dijkstra, Natasha
Sonneveld, Marjolein
Tom, Beril
Geelhoed-Duijvestijn, Nel
DIABETES, 2008, 57 : A591 - A591
[36] Efficacy and safety of biphasic insulin aspart 30 (BIAsp 30) in the subjects inadequately controlled, with OADs (oral antidiabetic drugs) - the Chinese OADs subgroups in the PRESENT study
Gao, Yan
Guo, Xiaohui
DIABETES, 2008, 57 : A573 - A573
[37] Comparison of biphasic insulin aspart (BIAsp30) and insulin glargine (IGlarg) during isoglycaemic clamp studies in persons with type 2 diabetes
Luzio, SD
Peter, R
Dunseath, GJ
Pauvaday, V
Owens, DR
DIABETES, 2004, 53 : A136 - A136
[38] Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: results from a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 in routine clinical practice
Shestakova, M. V.
Akil, Ballan
DIABETES MELLITUS, 2010, 13 (01): : 92 - 100
[39] Biphasic insulin aspart 30 improves postprandial glycemic control
Hermansen, K
Vaaler, S
Madsbad, S
Dalgaard, M
Begtrup, K
Lindholm, A
DIABETES, 2001, 50 : A95 - A95
[40] Effect of BIAsp 30 (biphasic insulin aspart 30) in combination with oral hypoglycaemic agents on glycaemic regulation in non-obese patients with type 2 diabetes
Lund, S. S.
Tarnow, L.
Nielsen, B. B.
Hansen, B. V.
Pedersen, O.
Parving, H. -H.
Vaag, A. A.
DIABETOLOGIA, 2006, 49 : 600 - 600

← 1 2 3 4 5 →